TGFB1 and cranioectodermal dysplasia: As previously discussed, in active CeD, IL-15 may interfere with immune regulation [23,24], therefore, treatments to improve the Treg population based on MSC therapies or the administration of cytokines known to promote their survival and expansion, as IL-10/TGF-β or inhibition of pro-inflammatory cytokines known to promote Treg dysfunction/cell death, such as anti-IL-15, could be also explored in CeD.